PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14572382

[CHROMAgar Candida with fluconazole: comparison with microdilution techniques].

María José Linares·Guadalupe Charriel·Francisco Solís·Manuel Casal
View original source ↗Export metadata ↓

Abstract

INTRODUCTION: The increasing incidence of fungal infections and the reported emergence of resistance to antifungal agents call for the development of techniques for in vitro measurement of antifungal susceptibility that will enable prediction of clinical outcome in patients suffering from these infections. METHODS. Susceptibility to fluconazole was tested in 156 clinical yeast isolates (109, Candida albicans; 19, C. parapsilosis; 12, C. glabrata; 11, C. tropicalis; 2, C. krusei; 1, C. pelliculosa; 1, C. lambica, and 1, Saccharomyces cerevisiae) and two control strains (C. krusei ATCC 6258 and C. parapsilosis ATCC 22019) using a simple screening method, CHROMAgar Candida with fluconazole (8 micro g/ml). This method was compared with two broth microdilution techniques: the reference method (NCCLS, document M27-A) and Sensititre(TM) YeastOne. RESULTS: Sensititre(TM) YeastOne showed close agreement with NCCLS M27-A results for all species (C. albicans and non albicans). CHROMAgar Candida with fluconazole (8 micro g/ml) yielded results matching those of the two broth microdilution methods for sensitive strains and strains highly resistant to fluconazole (C. krusei and C. glabrata), but performed less well with strains displaying dose-dependent susceptibility. CONCLUSION: These data suggest that CHROMAgar Candida with fluconazole (8 micro g/ml), appears to be a rapid, simple and sensitive screening method for detection and identification of fluconazole-susceptible and -highly resistant yeasts. However, additional methods should be used to determine whether positive growth in this medium is due to resistant strains (MIC > or = 64 micro g/ml) or to strains displaying dose-dependent susceptibility (MIC 16-32 micro g/ml). The usefulness of CHROMAgar Candida with fluconazole depends on the sample source and the species under study.

Explore related subjects

Antifungal AgentsCandidaChromogenic CompoundsColony Count, MicrobialCulture MediaDrug Resistance, FungalFluconazoleMicrobial Sensitivity TestsSaccharomyces cerevisiaeSpecies SpecificityComparative StudyEvaluation StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

María José Linares, Guadalupe Charriel, Francisco Solís, Manuel Casal. 2003. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].. https://pubmed.ncbi.nlm.nih.gov/14572382/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Machine learning-based drug susceptibility prediction from Candida genomic data.

OBJECTIVES: Invasive Candida infection is an increasing clinical concern, with antifungal resistance rising across multiple species. However, rapid and accurate antifungal susceptibility testing (AFST) remains limited in routine practice. The study evaluated species distribution and antifungal susceptibility of invasive Candida isolates in China and assessed the feasibility of combining whole-genome sequencing (WGS) with machine learning to predict minimum inhibitory concentrations (MICs). METHODS: Consecutive non-repetitive isolates were collected from 20 hospitals in 13 provinces during 2022-2023. MICs of nine antifungal agents were determined by broth microdilution, and WGS was performed for species accounting for >5% of the total isolates. Genomic 11-mer features were extracted and used to train random forest (RF), support vector machine (SVM), and extreme gradient boosting (XGBoost) models, followed by optimization of the best-performing algorithm. RESULTS: A total of 337 isolates were obtained from blood (n = 232) and sterile body fluids (n = 105), comprising C. albicans (n = 103), C. tropicalis (n = 71), C. parapsilosis (n = 67), and C. glabrata (n = 63). Non-albicans Candida showed higher azole and echinocandin resistance, with C. tropicalis notably resistant to azoles and C. glabrata to echinocandins. Among the three models, RF demonstrated the best performance on 304 sequenced isolates. The optimized RF model was evaluated by the receiver operating characteristic (ROC) curve analysis and achieved an average area under the ROC curve (AUC) of 0.979 (95% CI: 0.974-0.984), essential agreement over 90.1%, and categorical agreement over 93.2% across species. CONCLUSIONS: These findings underscore the clinical challenge posed by non-albicans Candida resistance, and indicate that WGS-based MIC prediction may offer a highly accurate reference for earlier antifungal therapy.

Antifungal Agents↗
PubMed2026

Clade-dependent antifungal resistance and susceptibility in Candidozyma auris: A global scoping review.

BACKGROUND: Candidozyma auris (formerly Candida auris) is an emerging multidrug-resistant fungal pathogen that has spread globally since its first identification in 2009 and is now classified as a critical-priority pathogen by the World Health Organization. Distinct genetic clades are associated with variations in geographic distribution, antifungal susceptibility, and resistance mechanisms; however, clade-specific evidence remains fragmented. AIMS: To systematically map global evidence on clade diversity, antifungal susceptibility patterns, resistance mechanisms, and clinical implications of C. auris. METHODS: A scoping review was conducted following PRISMA-ScR guidelines. Peer-reviewed primary studies published between 2009 and September 2025 were included if they reported clade attribution and antifungal susceptibility or resistance data. PubMed/MEDLINE, Scopus, and Web of Science were searched. Two reviewers independently screened studies and extracted data using a standardized form. RESULTS: Of 2050 records identified, 105 studies met inclusion criteria, representing 29 countries and diverse study designs. Whole-genome sequencing was the most common typing method. Antifungal susceptibility varied substantially across clades. High fluconazole resistance was consistently reported (MIC 4 to >256μg/mL). Echinocandins generally retained activity, although reduced susceptibility associated with FKS1 mutations was observed. Resistance mechanisms primarily involved mutations in ERG11, FKS1, and efflux-related genes. Studies also reported challenges in healthcare-associated transmission, environmental persistence, and diagnostic misidentification. CONCLUSIONS: C. auris exhibits marked clade-dependent variability in antifungal susceptibility and resistance mechanisms. These findings support the need for clade-informed interpretation of susceptibility data, standardized surveillance, improved diagnostics, and development of novel antifungal therapies.

Antifungal Agents↗
PubMed2026

Microbe Profile: Candidozyma auris: an emergent and resilient yeast and new antifungal strategies.

Candidozyma auris is an emerging opportunistic yeast that is important because of its multidrug resistance, persistence in healthcare environments and ability to cause outbreaks. Since its discovery in 2009 in Japan, it has rapidly spread worldwide and is now recognized as a major global public health threat and was recognized by the World Health Organization (WHO) in 2022 as a critical priority fungal pathogen. Distinct phylogeographic clades demonstrate simultaneous emergence on different continents, suggesting ecological or environmental triggers. Clinical management is complicated by frequent resistance to fluconazole, reduced susceptibility to amphotericin B and echinocandins, and frequent misidentification by traditional laboratory methods. Continued genomic surveillance, improved diagnostics and new antifungal strategies are urgently needed, supported by enhanced infection prevention and control procedures.

Antifungal Agents↗